Endoscopic ablation of low-grade dysplasia in Barrett’s esophagus: Have all the boxes been checked for us to move on?

In this issue of Gastrointestinal Endoscopy, Phoa et al1 report the findings from a mathematical model that examined the incremental cost effectiveness of radiofrequency ablation (RFA) for low-grade dysplasia (LGD) in Barrett's esophagus (BE). The base case scenario estimates for cost and effectiveness were derived from the Surveillance versus RadioFrequency ablation (SURF) trial, a randomized trial of patients with BE containing LGD, to receive RFA (ablation group, n = 68) or endoscopic surveillance (control group, n = 68).

http://ift.tt/2sxmkat